HRS-2189

DRUG3 trials

Sponsors

Shandong Suncadia Medicine Co., Ltd., Fudan University

Conditions

Advanced Unresectable or Metastatic Breast CancerColorectal Cancer MetastaticProstate Cancer Metastatic Disease

Phase 1

A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients

RecruitingNCT06679036

Shandong Suncadia Medicine Co., Ltd.Advanced Unresectable or Metastatic Breast Cancer

Start: 2025-01-21End: 2026-12-31Target: 300Updated: 2026-03-02

Phase 2

Study of HRS-2189 Combined HRS-5041 in Prostate Cancer

Not yet recruitingNCT06738745

Fudan UniversityProstate Cancer Metastatic Disease

Start: 2024-12-31End: 2027-08-31Target: 90Updated: 2024-12-18

An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer

Not yet recruitingNCT07061210

Fudan UniversityColorectal Cancer Metastatic

Start: 2025-07-01End: 2027-01-01Target: 20Updated: 2025-07-11